Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2A6 | P11509 | 5/20 | 0.60 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.60 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.60 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.60 |
| ▸ | MKNK1 | Q9BUB5 | 4/20 | 0.57 |
| ▸ | MKNK2 | Q9HBH9 | 4/20 | 0.57 |
| ▸ | KIF11 | P52732 | 1/20 | 0.56 |
| ▸ | CYP11B2 | P19099 | 2/20 | 0.52 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.51 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.51 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.51 |
| ▸ | CYP2E1 | P05181 | 1/20 | 0.51 |
| ▸ | CYP2B6 | P20813 | 1/20 | 0.51 |
| ▸ | CYP19A1 | P11511 | 2/20 | 0.49 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.49 |
| ▸ | PRMT6 | Q96LA8 | 1/20 | 0.49 |
| ▸ | CA12 | O43570 | 1/20 | 0.49 |
| ▸ | CA1 | P00915 | 1/20 | 0.49 |
| ▸ | CA2 | P00918 | 1/20 | 0.49 |
| ▸ | CA9 | Q16790 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23969884 | 0.94 | CYP2A6 (0.54) | CYP2A6CYP3A4ALDH1A1CYP1A2MKNK1 | |
| SCHEMBL17194812 | 0.83 | CYP2A6 (0.65) | CYP2A6CYP3A4ALDH1A1CYP1A2MKNK1 | |
| SCHEMBL29666522 | 0.83 | CYP2A6 (0.65) | CYP2A6CYP3A4ALDH1A1CYP1A2MKNK1 | |
| SCHEMBL29360677 | 0.82 | CYP2A6 (0.88) | CYP2A6CYP3A4ALDH1A1CYP1A2MKNK1 | |
| SCHEMBL13907273 | 0.82 | CYP2A6 (0.88) | CYP2A6CYP3A4ALDH1A1CYP1A2MKNK1 | |
| SCHEMBL24534338 | 0.82 | CYP2A6 (0.88) | CYP2A6CYP3A4ALDH1A1CYP1A2MKNK1 | |
| SCHEMBL2650388 | 0.81 | EPHX2 (0.58) | CYP2A6CYP3A4ALDH1A1CYP1A2MKNK1 | |
| SCHEMBL30098400 | 0.81 | EPHX2 (0.58) | CYP2A6CYP3A4ALDH1A1CYP1A2MKNK1 | |
| SCHEMBL15158543 | 0.80 | CYP1A2 (0.60) | CYP2A6CYP3A4ALDH1A1CYP1A2MKNK1 | |
| SCHEMBL5778503 | 0.80 | CYP2A6 (0.60) | CYP2A6CYP3A4ALDH1A1CYP1A2MKNK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3717459-B1 | COMPOUNDS | STEP PHARMA S A S (FR) | 2026-01-21 | — | — | EP | disclosed |
| WO-2023220440-A1 | OLIGONUCLEOTIDE COMPOSITIONS AND METHODS THEREOF | WAVE LIFE SCIENCES LTD. (SG) | 2023-11-16 | — | — | WO | disclosed |
| WO-2023091644-A2 | HSD17B13-RELATED DOUBLE STRANDED OLIGONUCLEOTIDE COMPOSITIONS AND METHODS RELATING THERETO | WAVE LIFE SCIENCES LTD. (SG) | 2023-05-25 | — | — | WO | disclosed |
| US-11655246-B2 | Aminothiazole compounds as inhibitors of CTPS1 | STEP PHARMA S.A.S. (FR) | 2023-05-23 | — | — | US | disclosed |
| WO-2023049218-A1 | DOUBLE STRANDED OLIGONUCLEOTIDE COMPOSITIONS AND METHODS RELATING THERETO | WAVE LIFE SCIENCES LTD. (SG) | 2023-03-30 | — | — | WO | disclosed |
| WO-2023017388-A1 | MODULATORS OF THE BETA-3 ADRENERGIC RECEPTOR USEFUL FOR THE TREATMENT OR PREVENTION OF HEART FAILURE | ARENA PHARMACEUTICALS, INC. (US) | 2023-02-16 | — | — | WO | disclosed |
| WO-2021237223-A1 | OLIGONUCLEOTIDE COMPOSITIONS AND METHODS THEREOF | WAVE LIFE SCIENCES LTD. (SG) | 2021-11-25 | — | — | WO | disclosed |
| WO-2021135183-A1 | ORGANIC COMPOUND, ORGANIC ELECTROLUMINESCENT DEVICE, AND ELECTRONIC APPARATUS | 陕西莱特光电材料股份有限公司 | 2021-07-08 | — | — | WO | disclosed |
| US-20210002269-A1 | COMPOUNDS | STEP PHARMA S.A.S. (FR) | 2021-01-07 | — | — | US | disclosed |
| EP-3492454-A1 | COMPOUNDS | Step Pharma S.A.S. (FR) | 2019-06-05 | — | — | EP | disclosed |
| EP-3492454-A1 | COMPOUNDS | Step Pharma S.A.S. (FR) | 2019-06-05 | — | — | EP | disclosed |
| US-20100087680-A1 | METHOD FOR PRODUCING BIARYL COMPOUND | SUMITOMO CHEMICAL COMPANY LIMITED (JP) | 2010-04-08 | — | — | US | disclosed |
| EP-1914221-A1 | PROCESS FOR PRODUCING BIARYL COMPOUND | Sumitomo Chemical Company, Limited (JP) | 2008-04-23 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11655246-B2 | Aminothiazole compounds as inhibitors of CTPS1 | CTPS1, CTPS2, TBXAS1 | CYP2A6 3540/4885CYP3A4 2897/4885ALDH1A1 3425/4885 |
| US-20100087680-A1 | METHOD FOR PRODUCING BIARYL COMPOUND | NISCH, BLVRB, BBOX1 | CYP2A6 333/4885CYP3A4 177/4885ALDH1A1 4339/4885 |
| US-20210002269-A1 | COMPOUNDS | UGT1A1, CYP1A1, CYP19A1 | CYP2A6 73/4885CYP3A4 22/4885ALDH1A1 181/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.